CClinicalTrials.gg
CompletedNCT04051073iSTABILISEUpdated May 18, 2022

Can Continuous Non-invasive Monitoring Improve Stability of Intraoperative Blood Pressure - A Feasibility Study.

A Phase 3 interventional study of Continuous non-invasive blood pressure monitoring in Hip Fractures, Hypotension on Induction and Intraoperative Hypotension, sponsored by University Hospital Birmingham NHS Foundation Trust. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-18.

Sponsored by University Hospital Birmingham NHS Foundation Trust · Phase 3, Interventional, and Prevention

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Background During anaesthesia for repair of a broken hip, many patients experience low blood pressure. There have been many studies showing that patients who experience low blood pressure during anaesthesia are at increased risk of sustaining kidney or heart damage, strokes, having a post-operative infection, or dying. During anaesthesia, in most cases blood pressure is monitored using a cuff which inflates on the arm (the 'normal' way blood pressure is measured in a GP practice or hospital ward). This gives a reading each time the cuff goes up and down, every 3-5 minutes typically. There is a less well used way to measure blood pressure, using an additional cuff on the finger which gives a constant, continuous measure of blood pressure. We think that using this monitor, rather than the 'standard' monitor, will mean that low blood pressure is recognised more quickly, therefore treated more quickly, and will lead to patients having less exposure to dangerously low blood pressures. If this is the case, we hope that it will reduce how often patients experience kidney or heart damage, have an infection after surgery, suffer a stroke, and reduce the risk of death.

Methodology To test this, we would need to run a large clinical trial comparing the continuous monitor to the standard monitor. This would be expensive and involve a great deal of work in a large number of hospitals, and so first we wish to determine whether the trial we would like to run is practical, and possible to deliver in the real world. To do this we plan to run the trial first on a small-scale feasibility (pilot) study, where we will recruit 30 patients, half of whom will have the standard monitor, and half of whom will have the continuous monitor. We will see what proportion of the patients who could enter the trial actually do so and complete it, and use it as an opportunity to iron out problems with the trial. If we find it is possible to run the trial on a small scale, we will apply for funding to run a full study. This will aim to answer the question of whether the continuous monitor improves the patient outcomes which were agreed during development with the patient public involvement group locally; rate of kidney damage, heart damage, stroke, post-operative infections, risk of death, and hospital length-of-stay.

Expected outcomes and implications. We anticipate we will find the trial to be feasible with amendments to the way it is run, and if this is the case, we will apply to run the full scale trial. If this shows that using the continuous monitor improves the patient outcomes above, then it would represent new, significant evidence that may lead to the NHS adopting it's use as 'standard care' during anaesthesia for repair of a broken hip, and would like lead to similar trials in other operations where patients may benefit in a similar way.

02

Conditions studied

  • Hip Fractures
  • Hypotension on Induction
  • Intraoperative Hypotension
  • Acute Kidney Injury
  • Myocardial Ischemia
  • Wound Infection
  • Perioperative/Postoperative Complications
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Provision of written informed consent
  2. Adult patients, undergoing surgical repair of neck of femur fracture
  3. Patient can understand and comprehend written and spoken English
  4. Patient's consultee can understand written and spoken English

Exclusion criteria

Exclusion Criteria:

  1. American Society of Anaesthesiologists (ASA) Class I patients
  2. Patients with device-specific exclusions; atrial fibrillation, Raynauds syndrome or disease, peripheral vascular disease, scleroderma, an arteriovenous shunt, valvular heart disease.
  3. Patients in whom a blood pressure cuff cannot be safely inflated on both arms for any reason (for example, lymphoedema).
  4. Patients in whom the treating anaesthetist has judged they will require invasive arterial pressure monitoring.
  5. Patients declining consent
  6. Patients in whom the treating anaesthetist will use total intravenous anaesthesia (TIVA)
  7. Patients in whom there is a >20mmHg difference between non-invasive cuff mean arterial pressure measurements made on opposite arms.
04

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Sham comparator
    Blinded

    CNAP monitoring applied, but screen and information not visible to treating anaesthetist

    Device: Continuous non-invasive blood pressure monitoring

  • Active comparator
    Unblinded

    CNAP monitoring applied and available in full to the treating anaesthetist

    Device: Continuous non-invasive blood pressure monitoring

Interventions

  • DeviceContinuous non-invasive blood pressure monitoring

    Continuous non-invasive blood pressure monitoring using CNAP

05

What researchers measure

Primary outcomes

  1. Feasibility Outcome - Proportion of recruited patients in whom CNAP was successfully applied and full data collected.

    Proportion of recruited patients in whom CNAP was successfully applied and full data collected.

    Time frame: Through to study completion, an average of 5-6 weeks per patient.

  2. Feasibility Outcome - Proportion of eligible patients successfully recruited

    The proportion of all those patients who are eligible during the recruitment period who are successfully enrolled into the trial.

    Time frame: Through to study completion, an average of 5-6 weeks per patient.

  3. Feasibility Outcome - Proportion of enrolled patients in whom there is a full data set recorded.

    Time frame: Through to study completion, an average of 5-6 weeks per patient.

  4. Feasibility Outcome - Proportion of enrolled patients in which we are able to record full follow up data.

    Time frame: Through to study completion, an average of 5-6 weeks per patient.

Secondary outcomes

  1. Intraoperative Outcomes - Nadir Blood Pressure

    The lowest mean arterial pressure recorded during surgery using the CNAP monitor

    Time frame: On the day of surgery only.

  2. Intraoperative Outcomes - Total time spent with a mean arterial pressure <80mmHg

    Time frame: On the day of surgery only.

  3. Intraoperative Outcomes - Total time spent with a mean arterial pressure <65mmHg

    Time frame: On the day of surgery only.

  4. Intraoperative Outcomes - Total time spent with a mean arterial pressure <55mmHg

    Time frame: On the day of surgery only.

  5. Intraoperative Outcomes - Total volume of intravenous fluids given

    Time frame: On the day of surgery only.

  6. Intraoperative Outcomes - Total dose of vasopressors given

    Broken down into totals of each separate vasopressor used.

    Time frame: On the day of surgery only.

  7. Post-operative Outcomes - Incidence of acute kidney injury in the 7 days post-operatively

    Outcomes as per standardised definitions from the European Perioperative Clinical Outcome standards

    Time frame: Assessed up to 7 days post-operatively.

  8. Post-operative Outcomes - Incidence of myocardial injury in the first 3 days after surgery

    Outcomes as per standardised definitions from the European Perioperative Clinical Outcome standards

    Time frame: Assessed up to 3 days post-operatively.

  9. Post-operative Outcomes - Incidence of stroke post-operatively

    Outcomes as per standardised definitions from the European Perioperative Clinical Outcome standards

    Time frame: Assessed up to 30 days post-operatively.

  10. Post-operative Outcomes - Incidence of post-operative surgical site infection

    As per CDC definitions

    Time frame: Assessed up to 30 days post-operatively.

  11. Post-operative Outcomes - Mortality

    Time frame: Assessed at 30 days post-operatively.

  12. Health Economic Outcome - Hospital Length of Stay

    Time frame: Assessed at hospital discharge, an average of 10-14 days

06

Study locations

1 site
  • MIDRU, Birmingham Heartlands Hospital
    Birmingham, West Midlands B95SS, United Kingdom
07

References and documents

Study documents

  • Protocol and statistical analysis plan · Jun 6, 2019
  • Informed consent form · Jun 6, 2019

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT04051073
Lead sponsor
University Hospital Birmingham NHS Foundation Trust
Collaborators
University of Warwick
Responsible party
William Rook (Academic Clinical Fellow, University of Warwick) — Principal investigator
First posted
Aug 9, 2019
Start date
Jun 13, 2019
Primary completion
Aug 5, 2019
Completion
Aug 5, 2019
Last update
May 18, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion